Why YourMD Only Prescribes FDA-Approved GLP-1 Medications

Compounded semaglutide was a legitimate option during the 2022–2024 shortage. It is not in 2026. A board-certified physician explains the regulatory history, the patient safety record, and why this is a permanent clinical policy — not a temporary compliance position.

Compounded semaglutide was a legitimate, legal option during the 2022–2024 shortage. It is not in 2026. YourMD has a permanent, absolute policy of prescribing zero compounded semaglutide or tirzepatide — ever. Here is the complete explanation of why, including the regulatory history, the patient safety record, and what you should know before choosing any GLP-1 telehealth platform.

How Compounded Semaglutide Became Legal — and Why That Changed

The story starts with the Ozempic and Wegovy shortage that began in 2022. The FDA placed semaglutide on its official drug shortage list. Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may compound copies of drugs on the FDA shortage list, even when a commercially available equivalent exists. For roughly two years, compounding semaglutide was a legally defensible practice while the shortage persisted.

In late 2024 and early 2025, Novo Nordisk increased manufacturing capacity significantly and Eli Lilly caught up on tirzepatide supply. The FDA removed both from the shortage list. The shortage exemption that allowed compounding evaporated. The FDA subsequently issued guidance making the legal position explicit: 503A pharmacies may not compound semaglutide or tirzepatide because they are not on the shortage list and a commercially available equivalent exists. Some platforms continue to offer "compounded semaglutide" in 2026 — the legal basis for doing so is, at best, contested.

What the FDA Found: The Patient Safety Record

The safety problems with compounded GLP-1 medications were not hypothetical. The FDA's MedWatch adverse event reporting system and direct FDA enforcement actions documented specific, serious patient harms:

Dosing errors from concentration confusion: Compounded semaglutide in concentrated multi-dose vials required patients to calculate and draw up the correct volume. Concentration errors — drawing up 10× the intended dose — led to severe nausea, vomiting, dehydration, and hospitalizations. The FDA issued a specific safety communication about this pattern.
"Semaglutide acetate" — a different compound: Multiple compounding pharmacies were producing and selling a product labeled as semaglutide that was actually semaglutide acetate — a different salt form that has not undergone FDA safety and efficacy review and is not the same as the approved drug (semaglutide sodium). The FDA issued a warning letter specifically addressing this substitution.
Potency failures: Independent lab testing found significant potency variation — some batches substantially below labeled concentration (treatment failure), others substantially above (overdose risk).
Sterility failures: Several 503A facilities received FDA warning letters related to sterility testing failures, environmental monitoring deficiencies, and inadequate beyond-use dating practices.
FTC enforcement: The Federal Trade Commission opened investigations into multiple DTC telehealth platforms for misleading advertising practices — specifically, marketing compounded semaglutide as equivalent to Wegovy or Ozempic without disclosing it was not the FDA-approved drug.

The Cost Difference Is Real — Here Is How to Think About It

The most common reason patients choose compounded GLP-1 is cost. During the shortage era, compounded semaglutide ran $100–$250/month versus Wegovy's $349/month through NovoCare savings — a real $100–$250/month difference. I am not going to pretend that gap doesn't matter to patients making real financial decisions.

What I will say is that the comparison needs to be made accurately:

The compounded option in 2026 is a product of uncertain legal status and variable quality — not a legal, equivalent alternative to the branded option
The FDA-approved option at $349/month through NovoCare is the same molecule (semaglutide) as that studied in the STEP trials, manufactured by Novo Nordisk under CGMP conditions, in the specific concentration and formulation that produced the clinical trial results
With commercial insurance that covers GLP-1 medications (coverage has expanded significantly in 2025–2026), your out-of-pocket on Wegovy may be as low as $25/month — making the economics of compounded medication far less compelling
YourMD's $79/month physician service fee + NovoCare medication is the full cost. No hidden fees, no markup on medication, no compounding shortcuts.

Our Policy: No Exceptions, No Future Exceptions

YourMD's policy on compounded GLP-1 medications is not a temporary regulatory compliance position. It is a clinical and ethical position:

We will not prescribe compounded semaglutide, compounded tirzepatide, compounded liraglutide, compounded orforglipron, or any other compounded GLP-1 receptor agonist — ever, under any circumstances, regardless of shortage status, patient request, or legal environment
All GLP-1 prescriptions are routed to NovoCare (Wegovy, Ozempic, Rybelsus) or LillyDirect (Zepbound, Mounjaro, Foundayo)
This policy is documented in our Terms of Service, prescribing policy page, GLP-1 clinical consent, and this article

If you are currently taking compounded semaglutide or tirzepatide and want to transition to FDA-approved branded medication, YourMD can help you do that — discontinuing the compounded product, confirming eligibility for manufacturer savings programs, and starting with the appropriate FDA-approved product at the right dose for where you are in your treatment.

How to Verify Any Platform's GLP-1 Medication

Before starting GLP-1 therapy through any telehealth platform, ask directly:

"Is the semaglutide or tirzepatide you prescribe FDA-approved branded Wegovy / Ozempic / Zepbound / Mounjaro — or a compounded formulation?"
If compounded: "What is the specific current legal basis for compounding semaglutide or tirzepatide now that both are off the FDA shortage list?"
"Is the product dispensed through NovoCare Pharmacy or LillyDirect, or through a compounding pharmacy?"
"Is the labeled active ingredient semaglutide sodium or semaglutide acetate?" (The FDA-approved drug is semaglutide sodium; the acetate salt form is not.)